Patents by Inventor Eva Corey

Eva Corey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
    Patent number: 9808472
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: November 7, 2017
    Assignees: Tokai Pharmaceuticals, Inc., University of Washington, University of Maryland, Baltimore
    Inventors: Vincent C. O. Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Douglas Jacoby
  • Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
    Patent number: 9387216
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: July 12, 2016
    Assignees: Tokai Pharmaceuticals, Inc., University of Washington, University of Maryland, Baltimore
    Inventors: Vincent C. O. Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Douglas B. Jacoby
  • BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIES
    Publication number: 20160038511
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 11, 2016
    Applicant: TOKAI PHARMACEUTICALS, INC.
    Inventors: Vincent C.O. Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Dr. Douglas Jacoby
  • BIOMARKERS FOR TREATMENT OF NEOPLASTIC DISORDERS USING ANDROGEN-TARGETED THERAPIES
    Publication number: 20150374721
    Abstract: Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.
    Type: Application
    Filed: July 6, 2015
    Publication date: December 31, 2015
    Inventors: Vincent Njar, Amina Zoubeidi, Karen Ferrante, Eva Corey, Douglas Jacoby